Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models

Abstract

Using a few initial measurements, we constructed robust patient-specific models of PCa immunotherapy, which were retrospectively validated by clinical trial results. Our results emphasize the potential value and feasibility of individualized model-suggested immunotherapy protocols.